Table 4.
Demographic and clinical characteristics after propensity score matching.
| Characteristic | Total (n = 888) | SIRI | p-value | |
|---|---|---|---|---|
| <4.57 (n = 444) | ≥4.57 (n = 444) | |||
| Demographics | ||||
| Age, years | 71.5 (58.6–82.8) | 71.8 (58.2–84.2) | 71.1 (58.8–81.6) | 0.245 |
| Male, n (%) | 454 (51.1) | 231 (52) | 223 (50.2) | 0.638 |
| Ethnicity, n (%) | 0.916 | |||
| White | 546 (61.5) | 276 (62.2) | 270 (60.8) | |
| Black | 91 (10.2) | 45 (10.1) | 46 (10.4) | |
| Others | 251 (28.3) | 123 (27.7) | 128 (28.8) | |
| Comorbidities | ||||
| Hypertension, n (%) | 685 (77.1) | 342 (77) | 343 (77.3) | 1.000 |
| Dyslipidemia, n (%) | 445 (50.1) | 217 (48.9) | 228 (51.4) | 0.502 |
| Previous stroke, n (%) | 95 (10.7) | 43 (9.7) | 52 (11.7) | 0.385 |
| CHF, n (%) | 253 (28.5) | 128 (28.8) | 125 (28.2) | 0.882 |
| PVD, n (%) | 103 (11.6) | 51 (11.5) | 52 (11.7) | 1.000 |
| Chronic pulmonary disease, n (%) | 185 (20.8) | 94 (21.2) | 91 (20.5) | 0.869 |
| Diabetes mellitus, n (%) | 295 (33.2) | 146 (32.9) | 149 (33.6) | 0.887 |
| Malignant cancer, n (%) | 58 (6.5) | 31 (7) | 27 (6.1) | 0.684 |
| Severe liver disease, n (%) | 14 (1.6) | 6 (1.4) | 8 (1.8) | 0.788 |
| Atrial fibrillation, n (%) | 371 (41.8) | 190 (42.8) | 181 (40.8) | 0.586 |
| Laboratory parameters | ||||
| WBC, 109/L | 11.6 (9.6–13.8) | 11.6 (9.3–13.7) | 11.8 (9.7–13.9) | 0.169 |
| Neutrophils percent, % | 81.7 (75.0–86.8) | 77.9 (69.8–84.0) | 84.0 (79.6–88.5) | <0.001 |
| Lymphocytes percent, % | 10.4 (6.8–15.6) | 15.0 (10.8–20.4) | 7.5 (5.0–10.1) | <0.001 |
| Monocytes percent, % | 5.2 (3.5–7.6) | 4.2 (2.9–6.2) | 6.2 (4.3–8.6) | <0.001 |
| Platelets, 109/L | 223.5 (168.5–288.5) | 223.0 (173.0–291.0) | 224.0 (167.0–285.0) | 0.612 |
| Hemoglobin, g/dl | 12.4 (10.6–13.9) | 12.4 (10.6–13.8) | 12.3 (10.7–14.0) | 0.764 |
| Serum glucose, mg/dl | 128.8 (107.7–160.8) | 128.1 (109.3–160.3) | 129.0 (107.2–161.2) | 0.863 |
| Serum creatinine, mg/dl | 1.1 (0.8–1.6) | 1.1 (0.8–1.6) | 1.1 (0.8–1.6) | 0.685 |
| Serum sodium, mmol/L | 141.0 (138.0–143.0) | 141.0 (138.0–143.0) | 140.0 (138.0–143.0) | 0.636 |
| Serum potassium, mmol/L | 4.3 (4.0–4.8) | 4.3 (4.0–4.8) | 4.3 (4.0–4.9) | 0.98 |
| Anion gap, mmol/L | 16.0 (14.0–19.0) | 16.0 (14.0–19.0) | 16.0 (14.0–19.0) | 0.358 |
| PT, second | 13.4 (12.0–15.5) | 13.5 (12.0–15.7) | 13.4 (12.1–15.4) | 0.653 |
| PTT, second | 30.1 (26.6–36.7) | 30.2 (26.8–36.6) | 29.9 (26.4–36.9) | 0.501 |
| NLR | 7.8 (4.8–12.7) | 5.1 (3.4–7.8) | 11.2 (7.8–17.6) | <0.001 |
| LMR | 2.0 (1.2–3.4) | 3.4 (2.6–4.9) | 1.2 (0.9–1.6) | <0.001 |
| PLR | 181.2 (117.2–300.9) | 132.3 (85.7–199.3) | 253.9 (170.7–412.5) | <0.001 |
| SIRI | 4.6 (2.6–7.4) | 2.6 (1.7–3.6) | 7.4 (5.7–11.2) | <0.001 |
| Scores | ||||
| SOFA | 4.0 (2.5–7.0) | 4.0 (2.0–7.0) | 4.0 (3.0–7.0) | 0.942 |
| GCS | 15.0 (14.0–15.0) | 15.0 (14.0–15.0) | 15.0 (14.0–15.0) | 0.894 |
| Treatment | ||||
| Thrombolysis, n (%) | 23 (2.6) | 11 (2.5) | 12 (2.7) | 1.000 |
| Thrombectomy, n (%) | 8 (0.9) | 4 (0.9) | 4 (0.9) | 1.000 |
| Clinical Outcomes | ||||
| LOS ICU, day | 3.7 (1.8–7.4) | 3.5 (1.7–7.3) | 3.9 (1.9–7.5) | 0.269 |
| LOS hospital, day | 9.7 (5.0–17.7) | 9.1 (4.9–17.6) | 9.9 (5.4–17.8) | 0.446 |
| Hospital mortality, n (%) | 172 (19.4) | 75 (16.9) | 97 (21.8) | 0.075 |
| 30-day mortality, n (%) | 237 (26.7) | 100 (22.5) | 137 (30.9) | 0.006 |
| 90-day mortality, n (%) | 298 (33.6) | 125 (28.2) | 173 (39) | <0.001 |
| 1-year mortality, n (%) | 374 (42.1) | 166 (37.4) | 208 (46.8) | 0.005 |
SIRI, Systemic Inflammation Response Index; CHF, Congestive heart failure; PVD, Peripheral vascular disease; WBC, white blood cell; PT, prothrombin time; APTT, activated partial thromboplastin time; NLR, Neutrophil-to-Lymphocyte Ratio; LMR, Lymphocyte-to-Monocyte Ratio; PLR, Platelet-to-Lymphocyte Ratio; SOFA, Sequential Organ Failure Assessment; GCS, Glasgow coma scale; LOS ICU, Length of ICU stay; LOS hospital, Length of hospital stay.